Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis

被引:74
作者
Adawi, A [1 ]
Zhang, Y
Baggs, R
Rubin, P
Williams, J
Finkelstein, J
Phipps, RP
机构
[1] Univ Rochester, Sch Med, Ctr Canc, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med, Dept Lab Anim Med, Rochester, NY 14642 USA
[4] Univ Rochester, Sch Med, Dept Radiat Oncol, Rochester, NY 14642 USA
[5] Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA
[6] Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA
[7] Univ Rochester, Sch Med, Dept Microbiol & Immunol, Rochester, NY 14642 USA
来源
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY | 1998年 / 89卷 / 03期
关键词
lung; ionizing radiation; inflammation; fibroblasts; cancer treatment;
D O I
10.1006/clin.1998.4606
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study investigated whether CD40-CD40 ligand (L) interactions are important in mediating ionizing radiation-induced lung toxicity, Radiotherapy is a key component in the management of malignant diseases and is a conditioning regimen for bone marrow transplantation. Unfortunately, radiation therapy is particularly toxic to the lung, potentially inducing a fatal pneumonitis and fibrosis, thus limiting its effectiveness. There are no therapies that protect against the development of radiation-induced lung toxicity. Using a mouse model of radiation-induced lung toxicity, a monoclonal anti-CD40L antibody (MR1) that disrupts CD40-CD40L, interactions was tested for the ability to reduce lung injury. C57BL/6 mice were pretreated with either nothing, MR1, or hamster IgG 24 h prior to a single dose of 15 Gray ionizing radiation to the thorax. During the following 26 weeks, mice continued to receive MR1 or hamster IgG twice per week. MR1 protected against death from radiation pneumonitis and fibrosis and dramatically reduced lung pathology as evidenced by a limited influx of inflammatory cells, minimal collagen deposition, and septal thickening MR1 also prevented radiation-induced pulmonary mastocytosis and blunted expression of cyclooxygenase-2, a proinflammatory enzyme responsible for prostaglandin synthesis, Disruption of CD40-CD40 interactions may offer a new mode of intervention to protect against radiation-induced pulmonary toxicity. (C) 1998 Academic Press.
引用
收藏
页码:222 / 230
页数:9
相关论文
共 42 条
[1]  
Adawi A, 1998, AM J PATHOL, V152, P651
[2]   MAST-CELLS AND BIOGENIC-AMINES IN RADIATION-INDUCED PULMONARY FIBROSIS [J].
ALDENBORG, F ;
NILSSON, K ;
JARLSHAMMAR, B ;
BJERMER, L ;
ENERBACK, L .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1993, 8 (01) :112-117
[3]   CD40 EXPRESSION BY HUMAN MONOCYTES - REGULATION BY CYTOKINES AND ACTIVATION OF MONOCYTES BY THE LIGAND FOR CD40 [J].
ALDERSON, MR ;
ARMITAGE, RJ ;
TOUGH, TW ;
STROCKBINE, L ;
FANSLOW, WC ;
SPRIGGS, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (02) :669-674
[4]   TRANSFORMING GROWTH-FACTOR-BETA AS A PREDICTOR OF LIVER AND LUNG FIBROSIS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ADVANCED BREAST-CANCER [J].
ANSCHER, MS ;
PETERS, WP ;
REISENBICHLER, H ;
PETROS, WP ;
JIRTLE, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (22) :1592-1598
[5]   Regression of pulmonary lesions produced by inhaled titanium dioxide in rats [J].
Baggs, RB ;
Ferin, J ;
Oberdorster, G .
VETERINARY PATHOLOGY, 1997, 34 (06) :592-597
[6]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[7]  
Blazar BR, 1997, J IMMUNOL, V158, P29
[8]  
BRIGHAM KL, 1983, CHEST, V83, pS70
[9]   PREVENTION OF COLLAGEN-INDUCED ARTHRITIS WITH AN ANTIBODY TO GP39, THE LIGAND FOR CD40 [J].
DURIE, FH ;
FAVA, RA ;
FOY, TM ;
ARUFFO, A ;
LEDBETTER, JA ;
NOELLE, RJ .
SCIENCE, 1993, 261 (5126) :1328-1330
[10]   CD40 EXPRESSION BY HUMAN FIBROBLASTS [J].
FRIES, KM ;
SEMPOWSKI, GD ;
GASPARI, AA ;
BLIEDEN, T ;
LOONEY, RJ ;
PHIPPS, RP .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 77 (01) :42-51